Literature DB >> 28862882

Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension.

Andrew J Bryant1, Vinayak Shenoy2, Chunhua Fu1, George Marek1, Kyle J Lorentsen1, Erica L Herzog3, Mark L Brantly1, Dorina Avram1, Edward W Scott4.   

Abstract

Pulmonary hypertension (PH) complicates the care of patients with chronic lung disease, such as idiopathic pulmonary fibrosis (IPF), resulting in a significant increase in morbidity and mortality. Disease pathogenesis is orchestrated by unidentified myeloid-derived cells. We used murine models of PH and pulmonary fibrosis to study the role of circulating myeloid cells in disease pathogenesis and prevention. We administered clodronate liposomes to bleomycin-treated wild-type mice to induce pulmonary fibrosis and PH with a resulting increase in circulating bone marrow-derived cells. We discovered that a population of C-X-C motif chemokine receptor (CXCR) 2+ myeloid-derived suppressor cells (MDSCs), granulocytic subset (G-MDSC), is associated with severe PH in mice. Pulmonary pressures worsened despite improvement in bleomycin-induced pulmonary fibrosis. PH was attenuated by CXCR2 inhibition, with antagonist SB 225002, through decreasing G-MDSC recruitment to the lung. Molecular and cellular analysis of clinical patient samples confirmed a role for elevated MDSCs in IPF and IPF with PH. These data show that MDSCs play a key role in PH pathogenesis and that G-MDSC trafficking to the lung, through chemokine receptor CXCR2, increases development of PH in multiple murine models. Furthermore, we demonstrate pathology similar to the preclinical models in IPF with lung and blood samples from patients with PH, suggesting a potential role for CXCR2 inhibitor use in this patient population. These findings are significant, as there are currently no approved disease-specific therapies for patients with PH complicating IPF.

Entities:  

Keywords:  C-X-C motif chemokine receptor 2; IL-8; myeloid-derived suppressor cell; pulmonary fibrosis; pulmonary hypertension

Mesh:

Substances:

Year:  2018        PMID: 28862882      PMCID: PMC5805999          DOI: 10.1165/rcmb.2017-0214OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  70 in total

1.  Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension.

Authors:  Eleni Vergadi; Mun Seog Chang; Changjin Lee; Olin D Liang; Xianlan Liu; Angeles Fernandez-Gonzalez; S Alex Mitsialis; Stella Kourembanas
Journal:  Circulation       Date:  2011-04-25       Impact factor: 29.690

2.  TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P.

Authors:  Lynne A Murray; Qingsheng Chen; Michael S Kramer; David P Hesson; Rochelle L Argentieri; Xueyang Peng; Mridu Gulati; Robert J Homer; Thomas Russell; Nico van Rooijen; Jack A Elias; Cory M Hogaboam; Erica L Herzog
Journal:  Int J Biochem Cell Biol       Date:  2010-10-29       Impact factor: 5.085

3.  Regulation of the inflammatory response: enhancing neutrophil infiltration under chronic inflammatory conditions.

Authors:  Zhen Bian; YaLan Guo; Binh Ha; Ke Zen; Yuan Liu
Journal:  J Immunol       Date:  2011-12-07       Impact factor: 5.422

4.  T-helper 17 cell polarization in pulmonary arterial hypertension.

Authors:  Aurélie Hautefort; Barbara Girerd; David Montani; Sylvia Cohen-Kaminsky; Laura Price; Bart N Lambrecht; Marc Humbert; Frédéric Perros
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

5.  Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II.

Authors:  Victoria J Burton; Alan M Holmes; Loredana I Ciuclan; Alexander Robinson; Jan S Roger; Gabor Jarai; Andrew C Pearce; David C Budd
Journal:  Blood       Date:  2011-09-07       Impact factor: 22.113

Review 6.  Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review.

Authors:  Shalvaree Vaidya; Clare L Hibbert; Elizabeth Kinter; Stefan Boes
Journal:  Lung       Date:  2016-11-19       Impact factor: 2.584

7.  The effect of continued hypoxia on rat pulmonary arterial circulation. An ultrastructural study.

Authors:  B Meyrick; L Reid
Journal:  Lab Invest       Date:  1978-02       Impact factor: 5.662

8.  Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat.

Authors:  Samantha Giordano; Xiangmin Zhao; Daisy Xing; Fadi Hage; Suzanne Oparil; John P Cooke; Jieun Lee; Karina H Nakayama; Ngan F Huang; Yiu-Fai Chen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-22       Impact factor: 4.733

9.  Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Authors:  Ganesh Raghu; Juergen Behr; Kevin K Brown; Jim J Egan; Steven M Kawut; Kevin R Flaherty; Fernando J Martinez; Steven D Nathan; Athol U Wells; Harold R Collard; Ulrich Costabel; Luca Richeldi; Joao de Andrade; Nasreen Khalil; Lake D Morrison; David J Lederer; Lixin Shao; Xiaoming Li; Patty S Pedersen; A Bruce Montgomery; Jason W Chien; Thomas G O'Riordan
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

10.  CXCR2 deficient mice display macrophage-dependent exaggerated acute inflammatory responses.

Authors:  Douglas P Dyer; Kenneth Pallas; Laura Medina-Ruiz; Fabian Schuette; Gillian J Wilson; Gerard J Graham
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

View more
  16 in total

1.  Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.

Authors:  Aline C Oliveira; Chunhua Fu; Yuanqing Lu; Mason A Williams; Liya Pi; Mark L Brantly; Corey E Ventetuolo; Mohan K Raizada; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-07-31       Impact factor: 5.464

2.  A checkpoint on innate myeloid cells in pulmonary arterial hypertension.

Authors:  Andrew J Bryant; Chunhua Fu; Yuanquing Lu; Mark L Brantly; Borna Mehrad; Lyle L Moldawer; Todd M Brusko; Evan L Brittain; James D West; Eric D Austin; Rizwan Hamid
Journal:  Pulm Circ       Date:  2018-12-18       Impact factor: 3.017

3.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

4.  Polymorphonuclear Leukocytes in Pulmonary Hypertension and Fibrosis: Not Always What They Appear to Be.

Authors:  Nedim Durmus; Gabriele Grunig
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

Review 5.  Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.

Authors:  Keshava Rajagopal; Andrew J Bryant; Sandeep Sahay; Nancy Wareing; Yang Zhou; Lavannya M Pandit; Harry Karmouty-Quintana
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

6.  PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension.

Authors:  Yapeng Cao; Xiaoyu Zhang; Lina Wang; Qiuhua Yang; Qian Ma; Jiean Xu; Jingjing Wang; Laszlo Kovacs; Ramon J Ayon; Zhiping Liu; Min Zhang; Yaqi Zhou; Xianqiu Zeng; Yiming Xu; Yong Wang; David J Fulton; Neal L Weintraub; Rudolf Lucas; Zheng Dong; Jason X-J Yuan; Jennifer C Sullivan; Louise Meadows; Scott A Barman; Chaodong Wu; Junmin Quan; Mei Hong; Yunchao Su; Yuqing Huo
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

7.  A wrinkle in time: circadian biology in pulmonary vascular health and disease.

Authors:  Andrew J Bryant; Elnaz Ebrahimi; Amy Nguyen; Christopher A Wolff; Michelle L Gumz; Andrew C Liu; Karyn A Esser
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-01       Impact factor: 5.464

8.  Vascular Endothelial Cell-Specific Connective Tissue Growth Factor (CTGF) Is Necessary for Development of Chronic Hypoxia-Induced Pulmonary Hypertension.

Authors:  Liya Pi; Chunhua Fu; Yuanquing Lu; Junmei Zhou; Marda Jorgensen; Vinayak Shenoy; Kenneth E Lipson; Edward W Scott; Andrew J Bryant
Journal:  Front Physiol       Date:  2018-02-27       Impact factor: 4.566

9.  Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling.

Authors:  Chunhua Fu; Yuanqing Lu; Mason A Williams; Mark L Brantly; Corey E Ventetuolo; Laurence M Morel; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Br J Pharmacol       Date:  2020-02-04       Impact factor: 9.473

10.  Myeloid-Derived Suppressor Cells Dampen Airway Inflammation Through Prostaglandin E2 Receptor 4.

Authors:  Chiel van Geffen; Astrid Deißler; Sandra Beer-Hammer; Bernd Nürnberg; Rupert Handgretinger; Harald Renz; Dominik Hartl; Saeed Kolahian
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.